🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "huge turning point" in the fight against increasingly resistant strains of the pathogen, according to scientists.

A Global Health Concern

Gonorrhoea infections are increasing globally, with data suggesting more than 82 million instances per year. Particularly high rates are reported in the African continent and nations within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. In England, cases have reached a all-time high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The approval of novel therapies for gonorrhoea is an significant and necessary step in the context of increasing worldwide cases, the spread of superbugs and the extremely scarce available drugs at this time.”

Medical experts are increasingly worried about the surge in treatment-resistant strains. The World Health Organization has designated it as a "priority pathogen". A tracking program revealed that the effectiveness of key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Treatment Options Secure Clearance

Zoliflodacin, alternatively called a brand name, was cleared by the American regulatory agency in recent days for combating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Experts anticipate that targeted use of this new drug will help hinder the development of resistance.

Gepotidacin, created by the drugmaker GSK, was also approved in close succession. This drug, which is additionally indicated for UTIs, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin was the result of a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to develop it.

“This approval represents a major breakthrough in the therapy of multidrug-resistant gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Testing Outcomes and Worldwide Availability

According to results released by a major medical journal, zoliflodacin eradicated more than 90% of uncomplicated infections. This places it at an equal footing with the existing first-line therapy, which uses two antibiotics. The research involved nearly 1,000 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, the non-profit has the ability to register and commercialise the drug in many low-income and middle-income countries.

Doctors directly involved have voiced optimism. The availability of a single-dose, oral treatment like this is hailed as a "game-changer" for gonorrhoea control. This is deemed essential to reduce the burden of the illness for individuals and to stop the proliferation of highly drug-resistant gonorrhoea worldwide.